IMMUNIC, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1200 AVENUE OF THE AMERICAS, NEW YORK, X1, 10036
Mailing Address
1200 AVENUE OF THE AMERICAS, NEW YORK, X1, 10036
Phone
(332) 255-9818
Fiscal Year End
1231
EIN
562358443
Financial Overview
FY2025
-$97.17M
Net Income
$-0.62
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 10, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | April 2, 2026 | View on SEC |
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 4, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 2, 2026 | View on SEC |
| 3 Initial insider ownership report | February 27, 2026 | View on SEC |
| 3 Initial insider ownership report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
Material Events
8-K
Leadership Change
April 10, 2026
High Impact
- Strategic transition to commercial-focused leadership to support late-stage drug development.
- Advancement of lead drug candidate, vidofludimus calcium, into pivotal Phase 3 clinical trials.
8-K
Financial Distress
January 6, 2026
High Impact
- IMMUNIC, INC. is moving its stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market due to its stock price falling below the $1.00 minimum bid price requirement.
- This transfer grants the company an additional 180 days, until June 22, 2026, to regain compliance with Nasdaq's minimum bid price rule.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.